Predictors of response to venetoclax plus hypomethylating agent therapy and survival in blastphase myeloproliferative neoplasm-Reference-Cited by-同舟云学术

Predictors of response to venetoclax plus hypomethylating agent therapy and survival in blastphase myeloproliferative neoplasm

Published:2022-12-15 Issue:5 Volume:108 Page:1423-1428
ISSN:1592-8721
Container-title:Haematologica
language:
Short-container-title:haematol

Author:

Gangat Naseema,Ilyas Rimal,McCullough Kristen,Begna Kebede H.,Al-Kali Aref,Patnaik Mrinal M.,Litzow Mark R.,Hogan William J.,Mangaonkar Abhishek,Alkhateeb Hassan,Shah Mithun V.,Elliott Michelle A.,Foran James M.,Badar Talha,Palmer Jeanne M.,Hanson Curtis A.,Pardanani Animesh,Tefferi Ayalew

Publisher

Ferrata Storti Foundation (Haematologica)

Subject

Hematology

Reference16 articles.

1. Tefferi A, Mudireddy M, Mannelli F. Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts. Leukemia. 2018; 32(5):1200-1210.

2. DiNardo CD, Jonas BA, Pullarkat V. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020; 383(7):617-629.

3. Gangat N, Morsia E, Foran JM, Palmer JM, Elliott MA, Tefferi A. Venetoclax plus hypomethylating agent in blast-phase myeloproliferative neoplasm: preliminary experience with 12 patients. Br J Haematol. 2020; 191(5):e120-e124.

4. Gangat N, Guglielmelli P, Szuber N. Venetoclax with azacitidine or decitabine in blast-phase myeloproliferative neoplasm: A multicenter series of 32 consecutive cases. Am J Hematol. 2021; 96(7):781-789.

5. Arber DA, Orazi A, Hasserjian R. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016; 127(20):2391-2405.

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Relapse and resistance in acute myeloid leukemia post venetoclax: improving second lines therapy and combinations;Expert Review of Hematology;2024-09-13

2. Optimizing Outcomes of Accelerated and Blast-Phase Myeloproliferative Neoplasms;Clinical Lymphoma Myeloma and Leukemia;2024-09

3. IDH1/2 inhibitor monotherapy in blast‐phase myeloproliferative neoplasms: A multicentre experience;British Journal of Haematology;2023-08-03

4. Blast phase myeloproliferative neoplasm: contemporary review and 2024 treatment algorithm;Blood Cancer Journal;2023-07-18

5. CPX-351 (Vyxeos™) treatment in blast-phase myeloproliferative neoplasm (MPN-BP): real-world experience in 12 consecutive cases;Blood Cancer Journal;2023-02-17